Tirzepatide denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Limits Tirzepatide Quantities — and Why You Can Appeal

Quantity-limit denials for tirzepatide from UnitedHealthcare reflect the plan's coverage policy restricting the number of doses, pens, or fills dispensed within a given period. These limits are intended to align with standard titration schedules but are not always calibrated to every patient's individualized clinical needs — creating a legitimate ground for appeal when your prescriber's plan differs from the plan's default allowance.

## Why This Denial Is Appealable

UHC's quantity limits must be applied consistently with the FDA-approved prescribing label. If your prescriber's prescribed quantity and titration timeline are within or supported by the label, and UHC's limit is more restrictive, that gap is directly appealable. Additionally, if your clinical circumstances (comorbidities, prior adverse effects at lower doses, clinical response patterns) justify a different quantity, your prescriber can document those reasons as a medical-necessity basis for the higher quantity.

## Federal Appeal Framework

• Internal appeal: ERISA §503 (employer plans) or applicable state law guarantees a full-and-fair review. The deadline is on your denial notice — typically 180 days.
• External review: Under ACA §2719, quantity-limit denials are eligible for independent external review after internal remedies are exhausted. The window is generally within approximately four months of the final internal denial.
• Expedited review: If the quantity restriction creates an urgent gap in therapy, expedited review is available — typically decided within 72 hours.

## Concrete Appeal Steps

1. Obtain the denial letter and identify UHC's stated quantity limit and the policy basis for it. 2. Confirm your prescribed quantity against the FDA-approved prescribing label — note where your prescription falls relative to label guidance. 3. Ask your prescriber to write a letter explaining the medical necessity of the prescribed quantity and titration pace, specifically addressing why the UHC limit is clinically insufficient for your case. 4. Submit the internal appeal with the documentation below. 5. If denied internally, file for external review.

## Documentation to Gather

• Prescription records: Documentation of the prescribed quantity and intended titration schedule.
• FDA prescribing label: The label section addressing dosing and titration, to compare against UHC's limit.
• Prescriber medical-necessity letter: Explains why the prescribed quantity is appropriate, why UHC's limit is insufficient, and ties the rationale to the patient's specific clinical situation.
• Clinical history: Chart notes documenting the condition severity and any clinical factors (prior treatment response, comorbidities) that bear on the dosing plan.

## Criteria-Mapping Structure

Create a table with UHC's quantity-limit criteria in the left column. In the right column, cite the FDA label language and the prescriber's clinical rationale for the prescribed quantity. If UHC's limit diverges from the label's guidance, highlight that gap explicitly in the appeal letter. Attach the FDA label page and the prescriber's letter as labeled exhibits.